American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Emapalumab for malignancy-associated hemophagocytic lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center experience
    Meeting Abstract

    Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Chang, T.; Galasso, N.; Stuver, R.; Khan, N.; Salles, G.; Moskowitz, A. J.; Vardhana, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs): Updated results from a phase I/II study
    Meeting Abstract

    Budde, E. L.; Bartlett, N. L.; Giri, P.; Schuster, S. J.; Assouline, S.; Yoon, S. S.; Fay, K.; Matasar, M. J.; Gutierrez, N. C.; Marlton, P.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • High-resolution single cell T-cell phenotyping of B-cell lineage lymphomas reveals unique immune signatures and potential targetable vulnerabilities
    Meeting Abstract

    El Daker, S.; Baik, J.; Dogan, A.; Zhu, M.; Roshal, M.; Galera, P. K.
    Blood (2022)

    Fulltext@MSK | Save
  • Mechanistic insights into immune related toxicities in subjects with relapsed/ refractory follicular lymphoma treated with zandelisib
    Meeting Abstract

    Sasi, B. K.; Martindale, S. P.; Shupe, S. J.; Fernandes, S. M.; Yadav, S.; Machado, J. H.; Phillips, T.; Zelenetz, A. D.; Brown, J. R.
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of single-agent zandelisib administered by intermittent dosing in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Final results of the tidal phase 2 study
    Meeting Abstract

    Zelenetz, A. D.; Jurczak, W.; Ribrag, V.; Linton, K. M.; Collins, G. P.; Bishton, M.; López Jiménez, J.; Dholaria, B.; Mengarelli, A.; Phillips, T. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • "Big Boom" (4 Gy x 1) radiation treatment (RT) versus "Big Boom" (2 Gy x 2) for non-Hodgkin lymphoma (NHL)
    Meeting Abstract

    Hajj, C.; Lebow, E. S.; Lee, J.; Fregonese, B.; Wijetunga, N. A.; Hubbeling, H.; Tringale, K. R.; Freret, M. E.; Imber, B. S.; Yahalom, J.
    Blood (2022)

    Fulltext@MSK | Save
  • Population pharmacokinetics and exposure-response analyses from Phase I-III studies support copanlisib dose selection in relapsed indolent non-Hodgkin lymphoma
    Meeting Abstract

    Moss, J.; Garmann, D.; Austin, R.; Hiemeyer, F.; Matasar, M. J.; Zinzani, P. L.; Beckert, V.; Soler, L. M.; Childs, B. H.; Morcos, P. N.
    Blood (2022)

    Fulltext@MSK | Save
  • Updated outcomes from the historical control study SCHOLAR-3 contextualizing ZUMA-3 results of brexucabtagene autoleucel (KTE-X19) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
    Meeting Abstract

    Shah, B. D.; Ghobadi, A.; Oluwole, O. O.; Logan, A. C.; Boissel, N.; Cassaday, R. D.; Leguay, T.; Bishop, M. R.; Topp, M. S.; Tzachanis, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Initial results from SELECT-AML-1, a Phase 2 Study of tamibarotene in combination with venetoclax and azacitidine in RARA-positive newly diagnosed AML patients ineligible for standard induction chemotherapy
    Meeting Abstract

    Kambhampati, S.; McMahon, C. M.; Eghtedar, A.; Pollyea, D. A.; de Botton, S.; Pigneux, A.; Cherry, M.; Ball, B. J.; Borthakur, G.; Cluzeau, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage
    Meeting Abstract

    Vekariya, U. M.; Sullivan-Reed, K.; Toma, M.; Nieborowska-Skorska, M.; Le, B. V.; Caron, M. C.; Kukuyan, A. M.; Podszywalow-Bartnicka, P.; Chitrala, K.; Atkins, J.; more...
    Blood (2022)

    Fulltext@MSK | Save